Toby Maher
Contact
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants Am J Respir Crit Care Med. 2023 May 01; 207(9):1194-1202. . View in PubMed
The causal relationship between gastro-esophageal reflux disease and idiopathic pulmonary fibrosis: A bidirectional two-sample Mendelian randomization study Eur Respir J. 2023 Apr 20. . View in PubMed
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random? Lancet Respir Med. 2023 Apr 04.. View in PubMed
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis Eur Respir Rev. 2023 Mar 31; 32(167). . View in PubMed
Change in gait speed and adverse outcomes in patients with idiopathic pulmonary fibrosis: A prospective cohort study Respirology. 2023 Mar 23. . View in PubMed
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial Respir Res. 2023 Mar 09; 24(1):71. . View in PubMed
PCSK6 and Survival in Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2023 Feb 13. . View in PubMed
MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis Respirology. 2023 05; 28(5):455-464. . View in PubMed
GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial Eur Respir J. 2023 03; 61(3). . View in PubMed
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression RMD Open. 2023 02; 9(1). . View in PubMed
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Lancet Respir Med. 2023 01; 11(1):45-54. . View in PubMed
Home monitoring in interstitial lung diseases Lancet Respir Med. 2023 01; 11(1):97-110. . View in PubMed
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study Lancet Respir Med. 2023 01; 11(1):65-73. . View in PubMed
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease Rheumatology (Oxford). 2023 02 06; 62(SI):SI43-SI53. . View in PubMed
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis J Comp Eff Res. 2022 Dec 20. . View in PubMed
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management Clin Rev Allergy Immunol. 2022 Dec; 63(3):472-489. . View in PubMed
Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort Lancet Digit Health. 2022 Dec; 4(12):e862-e872. . View in PubMed
Tackling the Neuropathic Cough of Idiopathic Pulmonary Fibrosis (IPF): More Needs to be Done Lung. 2022 Dec; 200(6):673-675. . View in PubMed
A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease Respir Res. 2022 Nov 11; 23(1):307. . View in PubMed
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography J Scleroderma Relat Disord. 2022 Oct; 7(3):168-178. . View in PubMed
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis ERJ Open Res. 2022 Oct; 8(4). . View in PubMed
ACR Open Rheumatol. 2022 Oct; 4(10):837-844. . View in PubMed
Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease Rheumatology (Oxford). 2022 Sep 29. . View in PubMed
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial Rheumatology (Oxford). 2022 Sep 16. . View in PubMed
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects Respir Res. 2022 Jul 05; 23(1):178. . View in PubMed
Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis Thorax. 2022 May 09. . View in PubMed
PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough Trials. 2022 Mar 02; 23(1):184. . View in PubMed
The role of precision medicine in interstitial lung disease Eur Respir J. 2022 Feb 03. . View in PubMed
A clinical short-cut to identifying short telomeres in idiopathic pulmonary fibrosis? Respirology. 2022 11; 27(11):916-917.. View in PubMed
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis Thorax. 2022 08; 77(8):829-833. . View in PubMed
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases Adv Ther. 2022 07; 39(7):3392-3402. . View in PubMed
Lung function trajectory in progressive fibrosing interstitial lung disease Eur Respir J. 2022 06; 59(6). . View in PubMed
Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis Respirology. 2022 03; 27(3):202-208. . View in PubMed
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study Chest. 2022 03; 161(3):728-737. . View in PubMed
Biomarker signatures for progressive idiopathic pulmonary fibrosis Eur Respir J. 2022 03; 59(3). . View in PubMed
Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim Analysis Ann Am Thorac Soc. 2022 03; 19(3):506-509. . View in PubMed
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease Eur Respir J. 2022 02; 59(2). . View in PubMed
Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework Adv Ther. 2022 02; 39(2):1045-1054. . View in PubMed
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use Adv Ther. 2022 02; 39(2):1081-1095. . View in PubMed
Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2022 03 01; 205(5):550-562. . View in PubMed
Interstitial lung diseases Lancet. 2022 09 03; 400(10354):769-786. . View in PubMed
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) Am J Respir Crit Care Med. 2022 05 01; 205(9):1084-1092. . View in PubMed
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective Am J Respir Crit Care Med. 2022 08 01; 206(3):247-259. . View in PubMed
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort Am J Respir Crit Care Med. 2022 06 15; 205(12):1440-1448. . View in PubMed
Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2022 07 01; 206(1):56-69. . View in PubMed
Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention? Am J Respir Crit Care Med. 2022 08 01; 206(3):244-246.. View in PubMed
Efficacy of Pirfenidone vsPlacebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Front Med (Lausanne). 2022; 9:897102. . View in PubMed
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary FibrosisReply. N Engl J Med. 2022 08 25; 387(8):762. . View in PubMed
Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease ERJ Open Res. 2022 Jan; 8(1). . View in PubMed
Reply to Fujimoto et al: The Need for a CYFRA 21-1 Cutoff Value to Predict Clinical Progression of IPF in Clinical Practice. Am J Respir Crit Care Med. 2022 09 01; 206(5):649-650. . View in PubMed
Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities? Am J Respir Crit Care Med. 2022 04 01; 205(7):743-744.. View in PubMed
Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry Am J Respir Crit Care Med. 2022 10 01; 206(7):903-905. . View in PubMed
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med. 2022 05 01; 205(9):e18-e47. . View in PubMed
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis N Engl J Med. 2022 06 09; 386(23):2178-2187. . View in PubMed
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD) BMJ Open Respir Res. 2021 Dec; 8(1). . View in PubMed
Global incidence and prevalence of idiopathic pulmonary fibrosis Respir Res. 2021 Jul 07; 22(1):197. . View in PubMed
50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study EBioMedicine. 2021 Jul; 69:103439. . View in PubMed
Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era ERJ Open Res. 2021 Jul; 7(3). . View in PubMed
Respir Res. 2021 Feb 05; 22(1):38. . View in PubMed
Reply Arthritis Rheumatol. 2021 12; 73(12):2354-2355. . View in PubMed
Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study Eur Respir J. 2021 10; 58(4). . View in PubMed
Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis? Ann Am Thorac Soc. 2021 08; 18(8):1285-1286.. View in PubMed
Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis Eur Respir J. 2021 07; 58(1). . View in PubMed
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial Eur Respir J. 2021 07; 58(1). . View in PubMed
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development Pharmacol Ther. 2021 06; 222:107798. . View in PubMed
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis Eur Respir J. 2021 05; 57(5). . View in PubMed
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression Respirology. 2021 05; 26(5):461-468. . View in PubMed
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial Arthritis Rheumatol. 2021 04; 73(4):671-676. . View in PubMed
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis Eur Respir J. 2021 02; 57(2). . View in PubMed
Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis Thorax. 2021 01; 76(1):73-82. . View in PubMed
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial Lancet Respir Med. 2021 01; 9(1):96-106. . View in PubMed
The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2021 02 01; 203(3):339-347. . View in PubMed
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study Am J Respir Crit Care Med. 2021 01 01; 203(1):136-139. . View in PubMed
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2021 07 01; 204(1):74-81. . View in PubMed
Enhanced IL-1ß Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis Front Immunol. 2021; 12:661811. . View in PubMed
Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten Am J Respir Crit Care Med. 2021 11 01; 204(9):1010-1011. . View in PubMed
Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World Front Med (Lausanne). 2021; 8:699644. . View in PubMed
DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis Am J Respir Crit Care Med. 2021 10 15; 204(8):954-966. . View in PubMed
Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis Commun Biol. 2021 03 23; 4(1):392. . View in PubMed
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells Am J Respir Crit Care Med. 2021 07 15; 204(2):197-208. . View in PubMed
Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study BMJ Open. 2021 06 02; 11(6):e048808. . View in PubMed
Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations Am J Respir Crit Care Med. 2021 03 15; 203(6):775-778. . View in PubMed
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review ERJ Open Res. 2021 Jan; 7(1). . View in PubMed
Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement Am J Respir Crit Care Med. 2021 07 15; 204(2):e3-e23. . View in PubMed
Itaconate controls the severity of pulmonary fibrosis Sci Immunol. 2020 Oct 23; 5(52). . View in PubMed
Author Correction: The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis Nat Commun. 2020 Sep 11; 11(1):4680. . View in PubMed
Shedding light on developmental drugs for idiopathic pulmonary fibrosis Expert Opin Investig Drugs. 2020 Aug; 29(8):797-808. . View in PubMed
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease Respir Res. 2020 Jul 23; 21(1):197. . View in PubMed
Chronic hypersensitivity pneumonitis; an enigmatic and frequently fatal disease Eur Respir Rev. 2020 Jun 30; 29(156). . View in PubMed
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease Clin Rheumatol. 2020 Apr; 39(4):1173-1179. . View in PubMed
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled avß6 integrin inhibitor Respir Res. 2020 Mar 26; 21(1):75. . View in PubMed
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials Respir Res. 2020 Jan 30; 21(1):36. . View in PubMed
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study Respirology. 2020 12; 25(12):1274-1282. . View in PubMed
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial Ann Rheum Dis. 2020 11; 79(11):1478-1484. . View in PubMed
Mixed Ventilatory Defects in Pulmonary Sarcoidosis: Prevalence and Clinical Features Chest. 2020 11; 158(5):2007-2014. . View in PubMed
Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype? Thorax. 2020 10; 75(10):901-903.. View in PubMed
Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype Chest. 2020 08; 158(2):646-659. . View in PubMed
Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020 08; 8(8):750-752.. View in PubMed
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact Eur Respir J. 2020 07; 56(1). . View in PubMed
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA Adv Ther. 2020 07; 37(7):3292-3298. . View in PubMed
Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis Adv Ther. 2020 05; 37(5):2460-2476. . View in PubMed
Predictors of progression in systemic sclerosis patients with interstitial lung disease Eur Respir J. 2020 05; 55(5). . View in PubMed
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation Eur Respir J. 2020 04; 55(4). . View in PubMed
Clinical quantification of the integrin avß6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) Eur J Nucl Med Mol Imaging. 2020 04; 47(4):967-979. . View in PubMed
Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent Eur Respir J. 2020 04; 55(4). . View in PubMed
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease Eur Respir J. 2020 02; 55(2). . View in PubMed
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial Eur Respir J. 2020 02; 55(2). . View in PubMed
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial Lancet Respir Med. 2020 02; 8(2):147-157. . View in PubMed
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2020 03 01; 201(5):564-574. . View in PubMed
Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisA Call to Arms. Am J Respir Crit Care Med. 2020 05 01; 201(9):1030-1032. . View in PubMed
Dynamics of human monocytes and airway macrophages during healthy aging and after transplant J Exp Med. 2020 03 02; 217(3). . View in PubMed
Translational pharmacology of an inhaled small molecule avß6 integrin inhibitor for idiopathic pulmonary fibrosis Nat Commun. 2020 09 16; 11(1):4659. . View in PubMed
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial JAMA. 2020 12 08; 324(22):2282-2291. . View in PubMed
The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis Int J Mol Sci. 2019 Nov 10; 20(22). . View in PubMed
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Respir Res. 2019 Sep 06; 20(1):205. . View in PubMed
Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort Respir Res. 2019 Jul 12; 20(1):148. . View in PubMed
Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use Pharmacoecon Open. 2019 Mar; 3(1):81-91. . View in PubMed
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design Adv Ther. 2019 11; 36(11):3059-3070. . View in PubMed
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease Expert Rev Clin Immunol. 2019 10; 15(10):1009-1017. . View in PubMed
Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis Eur Respir J. 2019 09; 54(3). . View in PubMed
King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference Eur Respir J. 2019 09; 54(3). . View in PubMed
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study Lancet Respir Med. 2019 09; 7(9):771-779. . View in PubMed
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Eur Respir J. 2019 09; 54(3). . View in PubMed
Management of Fibrosing Interstitial Lung Diseases Adv Ther. 2019 07; 36(7):1518-1531. . View in PubMed
Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis Eur Respir J. 2019 07; 54(1). . View in PubMed
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation Ann Am Thorac Soc. 2019 07; 16(7):927-930. . View in PubMed
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options Drugs Aging. 2019 06; 36(6):485-492. . View in PubMed
Can monocytes predict prognosis of idiopathic pulmonary fibrosis? Lancet Respir Med. 2019 06; 7(6):467-469.. View in PubMed
In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality Eur Respir J. 2019 05; 53(5). . View in PubMed
Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort Eur Respir J. 2019 05; 53(5). . View in PubMed
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Eur Respir J. 2019 03; 53(3). . View in PubMed
Regularized Latent Class Model for Joint Analysis of High-Dimensional Longitudinal Biomarkers and a Time-to-Event Outcome Biometrics. 2019 03; 75(1):69-77. . View in PubMed
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study Eur Respir J. 2019 02; 53(2). . View in PubMed
The potential impact of azithromycin in idiopathic pulmonary fibrosis Eur Respir J. 2019 02; 53(2). . View in PubMed
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities Arthritis Rheumatol. 2019 02; 71(2):182-195. . View in PubMed
Predicting outcomes in rheumatoid arthritis related interstitial lung disease Eur Respir J. 2019 01; 53(1). . View in PubMed
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone Eur Respir J. 2019 01; 53(1). . View in PubMed
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis Respir Med. 2019 01; 146:42-48. . View in PubMed
Sarcoidosis in the UK: insights from British Thoracic Society registry data BMJ Open Respir Res. 2019; 6(1):e000357. . View in PubMed
The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference BMJ Open Respir Res. 2019; 6(1):e000363. . View in PubMed
The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2019 07 15; 200(2):209-219. . View in PubMed
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis Nat Commun. 2019 01 02; 10(1):6. . View in PubMed
Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2019 11 01; 200(9):1146-1153. . View in PubMed
Computed Tomographic Biomarkers in Idiopathic Pulmonary FibrosisThe Future of Quantitative Analysis. Am J Respir Crit Care Med. 2019 01 01; 199(1):12-21. . View in PubMed
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) BMJ Open Respir Res. 2019; 6(1):e000422. . View in PubMed
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseReply. N Engl J Med. 2019 10 17; 381(16):1596-1597. . View in PubMed
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities QJM. 2019 02 01; 112(2):81-93. . View in PubMed
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis Sci Transl Med. 2019 09 25; 11(511). . View in PubMed
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2019 07 15; 200(2):199-208. . View in PubMed
Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2019 12 01; 200(11):1402-1413. . View in PubMed
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease N Engl J Med. 2019 06 27; 380(26):2518-2528. . View in PubMed
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study ERJ Open Res. 2018 Oct; 4(4). . View in PubMed
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice ERJ Open Res. 2018 Oct; 4(4). . View in PubMed
Could quality be the key in connective tissue disease-associated interstitial lung disease? Respirology. 2018 Jun 13.. View in PubMed
Improved quantitation and reproducibility in multi-PET/CT lung studies by combining CT information EJNMMI Phys. 2018 Jun 05; 5(1):14. . View in PubMed
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK Adv Ther. 2018 May; 35(5):724-736. . View in PubMed
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial Trials. 2018 Feb 05; 19(1):89. . View in PubMed
Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease EBioMedicine. 2018 Feb; 28:303-310. . View in PubMed
Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial Lancet Respir Med. 2018 10; 6(10):759-770. . View in PubMed
Gazing into the crystal ball: can treatment response be predicted in IPF? Lancet Respir Med. 2018 08; 6(8):570-572.. View in PubMed
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial Lancet Respir Med. 2018 08; 6(8):627-635. . View in PubMed
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review Pharmacoeconomics. 2018 07; 36(7):779-807. . View in PubMed
Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization Respirology. 2018 07; 23(7):687-694. . View in PubMed
Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema Respirology. 2018 06; 23(6):593-599. . View in PubMed
Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis Respirology. 2018 05; 23(5):498-506. . View in PubMed
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) Eur J Nucl Med Mol Imaging. 2018 05; 45(5):806-815. . View in PubMed
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018 02; 6(2):154-160.. View in PubMed
Rapidly Progressive Cystic Lung Disease Am J Respir Crit Care Med. 2018 07 15; 198(2):264. . View in PubMed
Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis? Am J Respir Crit Care Med. 2018 02 01; 197(3):283-284.. View in PubMed
Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views Respiration. 2018; 96(6):514-524. . View in PubMed
Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis Sci Rep. 2018 01 30; 8(1):1906. . View in PubMed
Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis Am J Respir Crit Care Med. 2018 09 15; 198(6):767-776. . View in PubMed
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial BMJ Open Respir Res. 2018; 5(1):e000289. . View in PubMed
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis Respiration. 2018; 95(5):317-326. . View in PubMed
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis Respiration. 2018; 96(4):314-322. . View in PubMed
The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis Respir Res. 2018 02 06; 19(1):25. . View in PubMed
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial BMJ Open Respir Res. 2018; 5(1):e000325. . View in PubMed
PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-ß1 production Sci Transl Med. 2018 09 26; 10(460). . View in PubMed
Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival Am J Surg Pathol. 2017 Dec; 41(12):1683-1689. . View in PubMed
Towards a global initiative for fibrosis treatment (GIFT) ERJ Open Res. 2017 Oct; 3(4). . View in PubMed
Coconut oil has less satiating properties than medium chain triglyceride oil Physiol Behav. 2017 Oct 01; 179:422-426. . View in PubMed
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries BMC Pulm Med. 2017 Sep 15; 17(1):124. . View in PubMed
Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study Thorax. 2017 Sep 07. . View in PubMed
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™) Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):75-81. . View in PubMed
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis Oncotarget. 2017 Jul 25; 8(30):48737-48754. . View in PubMed
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume Thorax. 2017 Apr; 72(4):340-346. . View in PubMed
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension J Manag Care Spec Pharm. 2017 Mar; 23(3-b Suppl):S3-S4. . View in PubMed
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis J Manag Care Spec Pharm. 2017 Mar; 23(3-b Suppl):S17-S24. . View in PubMed
An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study Lancet Respir Med. 2017 12; 5(12):946-955. . View in PubMed
Cough in fibrotic lung disease: An unresolved challenge Respirology. 2017 11; 22(8):1491-1492. . View in PubMed
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study Lancet Respir Med. 2017 11; 5(11):869-880. . View in PubMed
A lesson in plasticity: a 74-year-old man with plastic bronchitis Thorax. 2017 11; 72(11):1055-1057. . View in PubMed
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study Lancet Respir Med. 2017 11; 5(11):857-868. . View in PubMed
A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial Lancet Respir Med. 2017 10; 5(10):806-815. . View in PubMed
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis Arthritis Rheumatol. 2017 08; 69(8):1670-1678. . View in PubMed
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study Eur Respir J. 2017 08; 50(2). . View in PubMed
Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis Eur Respir J. 2017 07; 50(1). . View in PubMed
Home spirometry for idiopathic pulmonary fibrosis: ready for prime time? Eur Respir J. 2017 07; 50(1).. View in PubMed
Clinical trial research in focus: why do so many clinical trials fail in IPF? Lancet Respir Med. 2017 05; 5(5):372-374.. View in PubMed
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK Pharmacoeconomics. 2017 04; 35(4):479-491. . View in PubMed
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis Thorax. 2017 02; 72(2):137-147. . View in PubMed
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis Thorax. 2017 02; 72(2):148-153. . View in PubMed
Time for an International Consensus on Hypersensitivity PneumonitisA Call to Arms. Am J Respir Crit Care Med. 2017 09 15; 196(6):665-666. . View in PubMed
Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2017 06 15; 195(12):1640-1650. . View in PubMed
Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis Am J Respir Crit Care Med. 2017 08 15; 196(4):479-493. . View in PubMed
Update in Interstitial Lung Disease 2016 Am J Respir Crit Care Med. 2017 07 15; 196(2):132-138. . View in PubMed
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis Respir Res. 2017 02 01; 18(1):29. . View in PubMed
Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial Trials. 2017 04 28; 18(1):201. . View in PubMed
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial Trials. 2017 06 15; 18(1):275. . View in PubMed
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone Respiration. 2017; 93(6):415-423. . View in PubMed
Precision medicine in idiopathic pulmonary fibrosis QJM. 2016 Sep; 109(9):585-587. . View in PubMed
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis Clin Sci (Lond). 2016 Apr; 130(8):575-86. . View in PubMed
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? Trends Mol Med. 2016 Apr; 22(4):303-316.. View in PubMed
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns Eur Respir J. 2016 11; 48(5):1524-1526. . View in PubMed
Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted Respir Med. 2016 11; 120:131-133. . View in PubMed
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply Lancet Respir Med. 2016 09; 4(9):e48. . View in PubMed
Medicine and Me: a breath of fresh air for IPF Lancet Respir Med. 2016 08; 4(8):615-616. . View in PubMed
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF Thorax. 2016 08; 71(8):701-11. . View in PubMed
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis Eur Respir J. 2016 06; 47(6):1776-84. . View in PubMed
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis Lancet Respir Med. 2016 05; 4(5):381-9. . View in PubMed
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia BMC Genet. 2016 06 07; 17(1):74. . View in PubMed
Reply: Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis Am J Respir Crit Care Med. 2016 10 15; 194(8):1034-1035. . View in PubMed
Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis Am J Respir Crit Care Med. 2016 10 15; 194(8):989-997. . View in PubMed
Acute Exacerbation of Idiopathic Pulmonary FibrosisAn International Working Group Report. Am J Respir Crit Care Med. 2016 08 01; 194(3):265-75. . View in PubMed
Fantasy or Reality? Am J Respir Crit Care Med. 2016 11 15; 194(10):1182-1184.. View in PubMed
Recent advances in understanding idiopathic pulmonary fibrosis F1000Res. 2016; 5. . View in PubMed
An Unexplored Realm in the Search for Fibrosis Therapies? Am J Respir Crit Care Med. 2015 Dec 15; 192(12):1407-9.. View in PubMed
Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique Adv Ther. 2015 Oct; 32(10):929-43. . View in PubMed
Improved correction for the tissue fraction effect in lung PET/CT imaging Phys Med Biol. 2015 Sep 21; 60(18):7387-402. . View in PubMed
New guideline on treatment of idiopathic pulmonary fibrosis Lancet Respir Med. 2015 Sep; 3(9):e31-e32. . View in PubMed
Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease J Clin Epidemiol. 2015 Sep; 68(9):1019-27. . View in PubMed
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises Curr Opin Pulm Med. 2015 Sep; 21(5):470-8. . View in PubMed
Challenges in the classification of fibrotic ILD Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 03; 32 Suppl 1:4-9. . View in PubMed
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy Pharmacol Ther. 2015 Aug; 152:18-27. . View in PubMed
Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease Respirology. 2015 Jul; 20(5):834-45. . View in PubMed
Nintedanib in idiopathic pulmonary fibrosis Drugs Today (Barc). 2015 Jun; 51(6):345-56. . View in PubMed
Transcriptional phenotyping of fibrotic lung disease: a new gold standard? Lancet Respir Med. 2015 Jun; 3(6):423-4.. View in PubMed
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study Lancet Respir Med. 2015 Jun; 3(6):462-72. . View in PubMed
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Eur Respir Rev. 2015 Mar; 24(135):58-64. . View in PubMed
UK trainee experience in interstitial lung disease: results from a British Thoracic Society survey Thorax. 2015 Feb; 70(2):183. . View in PubMed
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Biomed Res Int. 2015; 2015:329481. . View in PubMed
Can we do better? Respirology. 2014 Nov; 19(8):1095-6.. View in PubMed
Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014 Nov; 2(11):933-942.. View in PubMed
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis Am J Respir Crit Care Med. 2014 Oct 15; 190(8):906-13. . View in PubMed
Case-based discussion from the Royal Devon and Exeter NHS Foundation Trust: a painful paradox Thorax. 2014 Aug; 69(8):779-81. . View in PubMed
Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register Thorax. 2014 Aug; 69(8):766-7. . View in PubMed
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Am J Respir Crit Care Med. 2014 Jul 15; 190(2):208-17. . View in PubMed
Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 08; 31(2):82-90. . View in PubMed
Respiratory microbiome in IPF: cause, effect, or biomarker? Lancet Respir Med. 2014 Jul; 2(7):511-3.. View in PubMed
Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era? Eur Respir J. 2014 May; 43(5):1233-6.. View in PubMed
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events Adv Ther. 2014 Apr; 31(4):375-91. . View in PubMed
Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology Respirology. 2014 Apr; 19(3):428-37. . View in PubMed
Immunosuppression for connective tissue disease-related pulmonary disease Semin Respir Crit Care Med. 2014 Apr; 35(2):265-73. . View in PubMed
Rituximab in severe, treatment-refractory interstitial lung disease Respirology. 2014 Apr; 19(3):353-9. . View in PubMed
Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis Thorax. 2014 Mar; 69(3):287-8. . View in PubMed
Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients Eur J Nucl Med Mol Imaging. 2014 Feb; 41(2):337-42. . View in PubMed
An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study Lancet Respir Med. 2014 Feb; 2(2):123-30. . View in PubMed
The treatment of idiopathic pulmonary fibrosis F1000Prime Rep. 2014; 6:16. . View in PubMed
Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease J Immunol. 2013 Nov 01; 191(9):4867-79. . View in PubMed
The role of infection in the pathogenesis of idiopathic pulmonary fibrosis Eur Respir Rev. 2013 Sep 01; 22(129):376-81. . View in PubMed
Provision of home mechanical ventilation and sleep services for England survey Thorax. 2013 Sep; 68(9):880-1. . View in PubMed
Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine Curr Opin Pulm Med. 2013 Sep; 19(5):460-5. . View in PubMed
The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease Respir Med. 2013 Sep; 107(9):1438-43. . View in PubMed
Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease Respir Res. 2013 Aug 02; 14:80. . View in PubMed
Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment Thorax. 2013 Aug; 68(8):780-1. . View in PubMed
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis Eur Respir J. 2013 Jul; 42(1):230-8. . View in PubMed
Exercise-induced haemoptysis: a thoroughbred cause? Thorax. 2013 Jun; 68(6):599-600.. View in PubMed
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis Nat Genet. 2013 Jun; 45(6):613-20. . View in PubMed
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Eur Respir Rev. 2013 Jun 01; 22(128):148-52. . View in PubMed
Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time Am J Respir Crit Care Med. 2013 Jun 01; 187(11):1271-2. . View in PubMed
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis Thorax. 2013 May; 68(5):436-41. . View in PubMed
Obliterative bronchiolitis in fibreglass workers: a new occupational disease? Occup Environ Med. 2013 May; 70(5):357-9.. View in PubMed
Year in review 2012: acute lung injury, interstitial lung diseases, sleep and physiology Respirology. 2013 Apr; 18(3):555-64. . View in PubMed
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis J Rheumatol. 2013 Apr; 40(4):435-46. . View in PubMed
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib Drug Des Devel Ther. 2013; 7:503-10. . View in PubMed
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status Thorax. 2013 Jan; 68(1):57-65. . View in PubMed
Successful treatment of progressive diffuse PEComatosis Eur Respir J. 2012 Dec; 40(6):1578-80. . View in PubMed
A clinical approach to diffuse parenchymal lung disease Immunol Allergy Clin North Am. 2012 Nov; 32(4):453-72. . View in PubMed
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts Adv Biosci Biotechnol. 2012 Oct; 3(6A):657-664. . View in PubMed
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire Thorax. 2012 Sep; 67(9):804-10. . View in PubMed
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy Eur Respir J. 2012 Sep; 40(3):641-8. . View in PubMed
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes Eur Respir J. 2012 Aug; 40(2):377-85. . View in PubMed
Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis Respirology. 2012 Jul; 17(5):861-8. . View in PubMed
Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia Respirology. 2012 May; 17(4):674-80. . View in PubMed
Year in review 2011: acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer Respirology. 2012 Apr; 17(3):554-62. . View in PubMed
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials Eur J Nucl Med Mol Imaging. 2012 Mar; 39(3):521-8. . View in PubMed
Significance of connective tissue disease features in idiopathic interstitial pneumonia Eur Respir J. 2012 Mar; 39(3):661-8. . View in PubMed
Elevated nocturnal desaturation index predicts mortality in interstitial lung disease Sarcoidosis Vasc Diffuse Lung Dis. 2012 Mar; 29(1):41-50. . View in PubMed
Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment Clin Chest Med. 2012 Mar; 33(1):69-83. . View in PubMed
In search of the fibrotic epithelial cell: opportunities for a collaborative network Thorax. 2012 Feb; 67(2):179-82. . View in PubMed
Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible causal relationship? Am J Surg Pathol. 2012 Feb; 36(2):228-34.. View in PubMed
Current and novel drug therapies for idiopathic pulmonary fibrosis Drug Des Devel Ther. 2012; 6:261-72. . View in PubMed
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008 Respiration. 2012; 84(3):200-6. . View in PubMed
Ambulatory oxygen in interstitial lung disease Eur Respir J. 2011 Oct; 38(4):987-90. . View in PubMed
Idiopathic pulmonary fibrosis-related pulmonary hypertension; an exercising diagnosis? Respirology. 2011 Apr; 16(3):381-3.. View in PubMed
Year in review 2010: interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer Respirology. 2011 Apr; 16(3):553-63. . View in PubMed
If it was good enough for Aristotle. . . . . Thorax. 2011 Mar; 66(3):183-84. . View in PubMed
Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis Am J Respir Crit Care Med. 2010 Jul 01; 182(1):73-82. . View in PubMed
Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc). 2010 Jul; 46(7):473-82. . View in PubMed
Sildenafil in idiopathic pulmonary fibrosis N Engl J Med. 2010 11 25; 363(22):2169; author reply 2170-1. . View in PubMed
Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention Respirology. 2010 Jan; 15(1):172-81. . View in PubMed
Pulmonary fibrosis associated with psychotropic drug therapy: a case report J Med Case Rep. 2009 Nov 16; 3:126. . View in PubMed
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury J Clin Invest. 2009 Sep; 119(9):2550-63. . View in PubMed
Lost in translation; from animal models of pulmonary fibrosis to human disease Respirology. 2009 Sep; 14(7):915-6. . View in PubMed
Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q) Am J Pathol. 2009 Apr; 174(4):1264-79. . View in PubMed
Understanding nonspecific interstitial pneumonia: the need for a diagnostic gold standard Am J Respir Crit Care Med. 2009 Feb 01; 179(3):255-6; author reply 256. . View in PubMed
Optimal treatment for idiopathic pulmonary fibrosis Thorax. 2008 Dec; 63(12):1120-1; author reply 1121. . View in PubMed
The diagnosis of idiopathic pulmonary fibrosis and its complications Expert Opin Med Diagn. 2008 Dec; 2(12):1317-31. . View in PubMed
Vibration response imaging technology in healthy subjects AJR Am J Roentgenol. 2008 Sep; 191(3):845-52. . View in PubMed
Native valve Aspergillus endocarditis complicating lung transplantation J Heart Lung Transplant. 2008 Aug; 27(8):910-3. . View in PubMed
Interstitial lung disease in systemic sclerosis: a simple staging system Am J Respir Crit Care Med. 2008 Jun 01; 177(11):1248-54. . View in PubMed
Reproducibility of dynamically represented acoustic lung images from healthy individuals Thorax. 2008 Jun; 63(6):542-8. . View in PubMed
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007 Nov; 30(5):835-9.. View in PubMed
CT findings of varicella pneumonia after lung transplantation AJR Am J Roentgenol. 2007 Jun; 188(6):W557-9. . View in PubMed
Acute breathlessness Br J Hosp Med (Lond). 2007 Mar; 68(3):M40-3. . View in PubMed
Highly polymorphic short tandem repeat analyses clarify complex molecular test results Diagn Mol Pathol. 2001 Sep; 10(3):179-89. . View in PubMed
Vascular density does not predict future metastatic disease in clinical stage 1 non-seminomatous germ cell tumours of the testis Histopathology. 1998 Mar; 32(3):217-24. . View in PubMed
Afferent input from peripheral chemoreceptors in response to hypoxia and amino acid neurotransmitter generation in the medulla Adv Exp Med Biol. 1996; 410:365-9. . View in PubMed
Distressful events in the ICU as perceived by patients recovering from coronary artery bypass surgery Heart Lung. 1994 Jul-Aug; 23(4):323-7. . View in PubMed
Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma Cancer Invest. 1994; 12(5):488-90. . View in PubMed
Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B J Natl Cancer Inst. 1993 Feb 17; 85(4):316-20. . View in PubMed
Surgical therapy for left ventricular aneurysmsA ten-year experience. Circulation. 1989 Jun; 79(6 Pt 2):I102-7. . View in PubMed
